Fiona Furlong
    Phone: +44 (0)28 9097 2296

    For media contact email
    or call +44(0)2890 973091.

    View graph of relations


    Receptor Pharmacology

    Cancer Pharmacology

    Mechanmis of Drug action

    Cell Signalling


    Methylated RNA Biomarkers

    Cancer Biology

    Ovarian Cancer

    Research Statement

    I am a University College Dublin Graduate and joined the School of Pharmacy, QUB, as a Lecturer in Pharmacology and cancer researcher in 2012.  Prior to joining QUB, I was a recipient of the Irish Cancer Society career development research fellowship in which I developed novel research on the role of the miR-433 microRNA as a biomarker of chemoresistance in ovarian cancer.  My research focus is on cancer pharmacology and stratified biomarker development and I primarily research the mechanism of action of anti-neoplastic agents.  Current projects include dissecting the molecular pharmacology of the histone deacetylase 6 (HDAC6) protein and the RNA demethylase enzymes.  New and emerging research from my group is focused on developing methods to detect methylated microRNA as next generation biomarkers of disease.  Areas of expertise include elucidating the mechanism of drug actions and downstream protein signalling in cell models of disease, cancer research and chemoresistance, cell and molecular biology, biomarker development and profiling microRNA in cells, tissue and plasma. My most significant research publications include studies of the miR-433 microRNA in chemoresistant ovarian cancer, IHC biomarker analyses and meta-analyse of the MAD2 protein in ovarian cancer prognosis.  Research from my group has been funded by the Irish Cancer Society, the Health Research Board of Ireland, BBSRC and MRC.

    Willingness to take PhD students


    PhD projects

    Open to PhD applications in the field of cancer research, cancer pharmacology, chemoresistance, cell and molecular biology, transcriptomics, biomarker development and drug discovery. Applications should meet the University's English language requirements, secured a source of funding, and who wish to pursue a research project in a relevant research topic.

    Exemplar PhD projects are detailed below:

    Mechanism of Drug activity in cancer

    Molecular Pharmacology of GPCRs

    Frequent Journals

    • Journal of the American Society of Nephrology

      ISSNs: 1046-6673

      Additional searchable ISSN (Electronic): 1533-3450

      American Society of Nephrology

      Scopus rating (2018): CiteScore 7.19 SJR 4.597 SNIP 2.358


    • The FASEB Journal

      ISSNs: 0892-6638

      Additional searchable ISSN (Electronic): 1530-6860


      Scopus rating (2018): CiteScore 4.32 SJR 2.065 SNIP 1.102


    • Oncotarget

      ISSNs: 1949-2553

      Impact Journals

      Scopus rating (2018): CiteScore 3.86 SJR 1.575 SNIP 0.904


    • Cancer Medicine

      ISSNs: 2045-7634

      John Wiley and Sons Ltd

      Scopus rating (2018): CiteScore 3.62 SJR 1.425 SNIP 1.081


    • BBA Clinical

      ISSNs: 2214-6474

      Elsevier BV

      Scopus rating (2018): CiteScore 3.83 SJR 1.34 SNIP 1.52


    View all »

    Contribution to conference papers, events and activities

    ID: 61580